Although this does not exclude the role of CJ on NOTCH1 wild-type cells, it confirms that T-ALL is sensitive to Ca2+-ATPase suppression, further supporting the need to explore SERCA inhibitors with binding sites different from that of thapsigargin. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.